Table 6.
Mean Levonadifloxacin Cmax and AUC on Day 5 Following Intravenous WCK 771 and Oral WCK 2349 Administered Twice Daily to Healthy US Subjects
| Dose | WCK 771 | WCK 2349 | ||
|---|---|---|---|---|
| Cmax (µg/mL) | AUC0–24 µg·h/mL | Cmax (µg/mL) | AUC0–24 µg·h/mL | |
| 600 mg, q12h | 15.84 | 183.68 | – | – |
| 800 mg, q12h | 18.00 | 208.97 | 18.34 | 211.45 |
| 1000 mg, q12h | 21.61 | 254.22 | 24.42 | 284.68 |
| 1200 mg, q12h | – | – | 23.36 | 287.90 |
Note: Data From: Chugh R, Lakdavala F, Bhatia A. Safety and pharmacokinetics of multiple ascending doses of WCK 771 and WCK 2349. Abstract P1268. 26th Eur congr clin microbial infect dis, Amsterdam, Netherlands. European Society of Clinical Microbiology and Infectious Diseases; 2016; Basel, Switzerland.45